Secondary prophylaxis therapy: What are the benefits, limitations and unknowns?

Haemophilia

Volumn 10, Issue 2, 2004, Pages 147-157

  Valentino, Leonard A ^a  

^a Rush Children's Hospital and Rush University Medical Center   (United States)

Author keywords

Arthropathy; Factor VIII; Haemophilia A; Haemorrhage; Secondary prophylaxis; Target joints

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; ARTHROPATHY; ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; HEALTH CARE COST; HEALTH INSURANCE; HEMARTHROSIS; HEMOPHILIA A; HUMAN; INTERMETHOD COMPARISON; NETHERLANDS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL CAPACITY; PHYSIOTHERAPY; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SECONDARY PREVENTION; SWEDEN; UNITED KINGDOM; UNITED STATES;

EID: 1542270966     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2003.00870.x     Document Type: Article

References (48)

1. National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) Recommendations 117, MASAC Recommendation Concerning Prophylaxis (Prophylactic Administration of Clotting Factor Concentrate to Prevent Bleeding), ?????: National Hemophilia Foundation, 2001.
2. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
3. CDC. Report on the Universal Data Collection Program (UDC). Atlanta, GA: Centers for Disease Control and Prevention, December 2002.
4. Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9 (Suppl. 1): 19-26.
5. Butler RB, McClure W, Wulff K. Practice patterns in haemophilia A therapy - a survey of treatment centres in the United States. Haemophilia 2003; 9: 549-54.
6. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
7. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
8. Escuriola Ettingshausen C, Funk M, Schmidt H, Weimer C, Kreuz W. Should prophylactic treatment in severe hemophilia A and B be started before the first joint bleeding? Blut 1998; 76 (Suppl. 1): P213.
9. Escuriola Ettingshausen C, Schmidt H, Weimer C, Funk M, Martinez Saguer I, Kreuz W. Long term prophylaxis in patients with haemophilia A and B. Annual Conference of the Standing Commission on Pediatrics of the Society for Thrombosis and Haemostasis Research, Halle an der Saale, Germany, June 10-12, 1999.
10. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
11. Kreuz W, Escuriola Ettingshausen C, Funk M, Pons S, Schmidt H, Kornhuber B. Gelenkveränderungen bei hämophilen Kindern durch frühzeitge Prophylaxe. Orthopäde 1999; 28: 341-6.
12. Yee TT, Beeton K, Harrington C, Miners A, Brown SA, Lee C. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2000; 6: 278.
13. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41.
14. Berntorp E, Astermark J, Björkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9 (Suppl. 1): 1-4.
15. Ljung R. Second Workshop of the European Paediatric Network for Haemophilia Management, 17-19 September 1998 in Vitznau/Switzerland. Haemophilia 1999; 5: 286-91.
16. Ljung RC. Can haemophilic arthropathy be prevented? Br J Haematol 1998; 101: 215-9.
17. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-7.
18. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
19. Loverin JA, Mensah P, Nokes TJC. Limited prophylaxis in adults with severe haemophilia: a pilot study. Haemophilia 2000; 6: 274-5.
20. Saba HI, Tannenbaum B, Morelli G, Azam R, Atanes I, Nichols C. Factor prophylaxis in the management of adult haemophiliacs. Haemophilia 2000; 6: 276-7.
21. Rodriguez-Merchan EC. Orthopaedic assessment in haemophilia. Haemophilia 2003; 9 (Suppl. 1): 65-74.
22. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 30: 3-6.
23. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop 1980: 153-9.
24. Kilcoyne RF, Nuss R. Radiological assessment of haemophilic arthropathy with emphasis on MRI findings. Haemophilia 2003; 9 (Suppl. 1): 57-64.
25. Pollmann H, Richter H, Ringkamp H, Jurgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999; 158 (Suppl. 3): S166-70.
26. van den Berg HM, Fischer K, van der Bom JG, Roosendaal G, Mauser-Bunschoten EP. Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies. Haemophilia 2002; 8 (Suppl. 2): 43-6.
27. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand 1965; (Suppl. 77): 3-132.
28. van den Berg HM, Nieuwenhuis HK, Mauser-Bunschoten EP, Roosendaal G. Hemophilia prophylaxis in the Netherlands. Sem Hematol 1994; 31: 13-5.
29. Fischer K, van Hout BA, van der Bom JG, Grobbee DE, van den Berg HM. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol 2002; 43: 528-32.
30. Gringeri A. Prospective controlled studies on prophylaxis: an Italian approach. Haemophilia 2003; 9 (Suppl. 1): 38-43.
31. van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
32. Panicker J, Warrier I, Lusher J. The impact of prophylaxis on children with severe haemophilia. Haemophilia 2002; 8: 489-90.
33. Yee TT, Beeton K, Griffioen A et al. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8: 76-82.
34. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
35. Miners AH, Sabin CA, Tolley KH, Lee CA. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med 1998; 244: 515-22.
36. Brackmann HH, Eickhoff HJ, Oldenburg J, Hammerstein U. Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. Haemostasis 1992; 22: 251-8.
37. Dzinaj T, Funk M, Schmidt H et al. Radiological score in paediatric haemophilic patients with early and late onset of factor VIII-prophylaxis. Thromb Haemost 1996; 76: 630-1.
38. Cohen A, White E, Bernstein C et al. Effects of secondary prophylaxis in hemophilia children with frequent hemarthrosis. Transfusion 1997; 37: 534-5.
39. Rocino A, Salerno E, Capasso F et al. Secondary prophylaxis in severe haemophilia A: results in preventing further joint damage. Thromb Haemost 1999; 82 (Suppl.): 610, Abstract 1923A.
40. Guerois C, Lambert T, Fressinaud E, Peynet J, Pouplard C, Gruel Y. Retrospective analysis of secondary prophylaxis in French haemophiliacs using one recombinant factor VIII, and defense for primary prophylaxis treatments. Haemophilia 2000; 6: 273-4.
41. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001; 7: 99-102.
42. Fischer K, Van Der Bom JG, Prejs R et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001; 7: 544-50.
43. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr 1996; 129: 424-31.
44. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S. A prophylactic program in the United States: experience and issues. Sem Hematol 1994; 31: 10-2.
45. Miners AH, Sabin CA, Tolley KH, Lee CA. The changing patterns of factor VII1 (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994. Haemophilia 1998; 4: 4-9.
46. Schramm W, Berger K. Economics of prophylactic treatment. Haemophilia 2003; 9 (Suppl. 1): 111-6.
47. Cross S, Koerper M. Prophylaxis in hemophilia - primary, secondary, and beyond. Symposium Report, The Marketing Research Bureau, Inc., 1999.
48. Mazzucconi MG, Santoro C, Bernasconi S, Bizzoni L, Redi R. Prophylaxis with recombinant FVIII (rFVIII) in a single Haemophilia Centre. Haemophilia 2002; 8: 489.